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Abstract 
In spite of decades of research, the Acute Respiratory Distress Syndrome (ARDS) continues to have 
an unacceptably high mortality and morbidity. Mesenchymal stromal cells (MSCs) present a 
promising candidate for the treatment of this condition and have demonstrated benefit in preclinical 
models. MSCs, which are a topic of growing interest in many inflammatory disorders, have already 
progressed to early phase clinical trials in ARDS. Whilst a number of their mechanisms of effect have 
been elucidated, a better understanding of the complex actions of these cells may pave the way for 
MSC modifications which might enable more effective translation into clinical practice. 
ARDS  
ARDS is a devastating clinical disorder with a variety of aetiologies that induces an excessive 
inflammatory response. Widespread damage to the alveolar compartment ensues leading to the 
development of hallmark traits of ARDS such as hypoxia and pulmonary oedema(1). First described by 
Ashbaugh et al. in 1967 as the “acute onset of tachypnoea, hypoxemia, and loss of compliance”(2), 
ARDS has since been studied extensively. Presently the diagnosis requires that the condition develop 
within one week of the underlying insult, that bilateral lung infiltrates are evident through chest 
imaging and that respiratory failure cannot be wholly attributed to cardiac failure and hydrostatic 
oedema(3).  
Epidemiological studies report that mortality and morbidity associated with ARDS remains 
significant; rates vary from 25-40% and are dependent on the severity of the condition(3-5). There has 
been an improvement in mortality rates over time which reflect improvements in supportive care 
and in particular the preferential use of protective lung ventilation and other interventions to limit 
injurious ventilation(4, 6, 7). An effective therapeutic intervention which targets the underlying 
pathophysiology remains elusive(8) and many candidates which initially showed promise in preclinical 
studies have been of no clinical benefit with regards to mortality(9-13). The heterogeneous patient 
population coupled with a complex pathophysiology underlying the development of ARDS may 
explain the difficulty of the challenge that researchers are faced with in developing a therapy for 
ARDS. It is arguable that a therapy which targets multiple aspects of the pathophysiology of ARDS 
may have greater potential to improve outcomes. 
MSCs 
MSCs are a heterogeneous population of cells found in nearly all adult tissues including bone 
marrow, placenta, adipose tissue, skin and skeletal muscle(14-16). With the capacity to differentiate 
into cells of both mesenchymal and non-mesenchymal lineage, the potential application in 
regenerative medicine has been widely recognised(17-19).  
Further study has identified additional qualities which may dramatically broaden the scope of their 
therapeutic use. One major obstacle for tissue and organ transplantation is rejection and careful 
donor-recipient matching is required. In contrast, there is evidence that MSCs have inherently low 
immunogenicity and are generally well tolerated even when administered in an allogeneic fashion(20, 
21).  
In non-inflammatory conditions MSCs do not express MHC class II but expression is triggered by 
stimulation with IFN-γ. However they appear to lack expression of CD40, CD80 and CD86, key co-
stimulatory molecules required for T cell activation, which may explain recipient tolerance to these 
cells(22). Conflicting evidence has been reported that MSCs are not in fact immune privileged and do 
elicit immune responses in non-matched hosts(23, 24). These confounding results could be a result of 
the inconsistencies in the source of MSCs or perhaps the disease setting itself. Regardless, it seems 
that MSCs may not be universally tolerated in all non-matched patients and emphasizes the need for 
further study, including testing patients who receive MSCs for development of anti-HLA antibodies. 
Another potential concern with using stem cells therapeutically is in their tendency to become 
tumorigenic as has been shown with embryonic stem cells(25). Adipose-derived MSCs have been 
shown to maintain genetic stability for at least 12 passages in vitro and show no evidence of tumour 
development when given intravenously to immunodeficient mice at a range of doses(26, 27). Bernardo 
et al. similarly show that human bone marrow-derived MSCs when cultured to passage 25 show no 
alteration in telomerase activity or telomere length, again suggesting genetic stability(28). In contrast, 
another study showed malignant transformation of human MSCs in long term culture(29) although 
these cells were cultured in vitro for up to 105 weeks. It is likely that MSCs used therapeutically will 
be cultured for a much shorter period. Furthermore, MSCs have also been reported to promote 
breast cancer metastasis in vitro(30). With conflicting data regarding their tumorigenicity, it will be 
imperative to have stringent quality control processes in place to monitor their safety when 
administrated to patients, including long-term follow-up. 
The immunomodulatory actions of MSCs are well documented; interactions with T lymphocytes, NK 
cells and dendritic cells amongst others confer them with many regulatory functions in terms of both 
innate and adaptive immunity(31, 32). MSCs can inhibit T cell proliferation or promote regulatory T 
cells via induction of an anti-inflammatory macrophage phenotype(33, 34). They suppress proliferation, 
cytokine production and cytotoxicity of NK cells towards HLA class I expressing targets and can 
prevent the differentiation of monocytes into dendritic cells as well as decrease the antigen 
presentation capacity of mature dendritic cells(35, 36). MSCs immunosuppressive effects also prolong 
the survival of allogeneic grafts given in a number of settings(37, 38).  
Moreover, MSCs naturally home to sites of injury when administered intravenously. Stromal cell-
derived factor-1 (SDF-1) is produced by resident cells in response to injury(39, 40). The chemotactic 
receptor CXCR4, which binds SDF-1, is expressed on a subset of MSCs and provides an important 
mechanism in MSC homing(41). A recent study also found SDF-1 ligation increased Akt kinase 
signalling and enhanced paracrine factor secretion emphasizing MSC responsiveness to physiological 
cues in their environment(42). Rolling and adhesion of MSCs along blood vessels is facilitated by P-
selectin and VCAM-1 expression on endothelial cells and in vivo imaging has demonstrated the 
interaction of MSCs with platelets and neutrophils to form clusters, thereby mediating MSC 
trafficking to inflamed sites(43, 44). It is important to note that MSCs are relatively large cells and have 
a tendency to become entrapped in small diameter vessels, with reports of sequestration to the lung 
microvasculature(45, 46). Another study further investigated the in vivo distribution of MSCs after 
infusion using real time imaging. Gao et al. observed MSC accumulation primarily in the lungs 
immediately after systemic infusion with smaller numbers in the liver and spleen. By 48 hours there 
is a shift of MSCs from the lungs towards the liver(47). The homing of MSCs to the lung may be 
pertinent to their efficacy in ARDS, as it allows targeted paracrine factor delivery.  
 
 
MSCs in preclinical disease models of ARDS 
Given these data, MSCs have been tested in a range of preclinical models of inflammatory conditions 
including acute renal failure, myocardial infarction and sepsis where they were found to be of 
benefit(48-50). The therapeutic potential of MSC in ARDS has been studied extensively during the past 
decade, using different MSC sources, treatment regimens and models of lung injury. Intrapulmonary 
delivery of murine bone-marrow derived MSCs into mice 4 hours after endotoxin-induced lung injury 
improved survival, reduced oedema and improved barrier permeability(51). These MSCs, when given 
intratracheally, were also protective in a live E.coli pneumonia model of lung injury, given 4 hours 
after infection(52). In a bleomycin-induced lung injury model in mice, intravenous administration of 
human umbilical cord MSCs 24 hours after injury resulted in reduced fibrosis and inflammation(53). 
Rat and human MSCs also have the capacity to improve repair of the lung following ventilator-
induced lung injury(54, 55). MSCs are similarly therapeutic in larger animal models; in a sheep model of 
ARDS induced by smoke inhalational and bacterial pneumonia human MSCs improved oxygenation 
and pulmonary oedema(56). Providing further evidence of the potential of MSCs in patients with 
ARDS, Lee et al. developed a human ex vivo lung perfusion model of endotoxin-induced and live 
bacteria-induced injury. Allogeneic MSCs given 1 hour after injury improved barrier permeability and 
alveolar fluid clearance whether given intratracheally or intravenously(57, 58).  
Mechanisms of MSC effect in lung injury  
One of the most valuable qualities which can be attributed to MSCs, which pharmacologic therapies 
lack, is the ability to actively respond to the local environment. This allows MSCs to have an 
individual and potentially varied therapeutic effect targeting multiple aspects of ARDS. A number of 
mechanisms by which MSC act have been identified.    
Engraftment 
Considering the loss of integrity of the alveolar epithelium following injury it was hypothesized that 
MSCs, with their pluripotency, may engraft into the epithelium and so contribute to regeneration. 
Whilst engraftment of MSCs into the lung epithelium is documented, it appears to be a rare event in 
the context of lung injury with reports of less than 5% engraftment occurring and so it is likely this 
does not represent the primary mechanism of their effect(51, 59-63).  
Paracrine factors 
Given the seemingly low capacity for engraftment into the alveolar epithelium, it is generally 
considered that the secretion of paracrine factors is one of the primary mechanisms of their effect. A 
number of groups show that keratinocyte growth factor (KGF), produced by MSCs, is essential for 
the restoration of alveolar epithelium permeability and alveolar fluid clearance after injury by 
rescuing the activity of the sodium channel ENaC(57, 64, 65). Similarly, angiopoietin-1 was found to be 
responsible for the MSC protective effects on type II alveolar epithelial cell permeability in an in vitro 
model(66).  
One worry with a therapy having anti-inflammatory effects being utilized in an infectious setting, as 
is often the case in ARDS, is that the host’s ability to combat infection may be hindered. Interestingly 
however, MSC administration in models of sepsis and ARDS triggered by live bacteria consistently 
results in improved bacterial clearance despite reduced inflammation. The antimicrobial effect of 
MSCs is partially explained by their ability to enhance phagocytosis by cells of the innate immune 
system. In two different murine sepsis models, MSCs were found to increase phagocytic capacity of 
CD11b positive cells and blood monocytes(48, 67). Neutrophils also demonstrate increased phagocytic 
activity with the influence of MSC, as seen by Hall et al. in a cecal ligation and puncture model of 
sepsis. Moreover, the depletion of neutrophils from these mice abrogated the beneficial effect of 
MSCs(68). MSC-derived KGF reduced bacterial load in the ex vivo perfused human lung injured with E. 
coli which was associated with increased phagocytosis by alveolar macrophages, potentially by the 
upregulation of GM-CSF in the BALF. In vitro experiments, also showed a pro-survival effect of MSC-
derived KGF on human monocytes(58). Additional antimicrobial activity is exerted by MSCs through 
the secretion of antimicrobial peptides and proteins such as human cathelicidin, LL-37 and lipocalin-
2 which binds the bacterial siderophore responsible for iron uptake, an essential micronutrient for 
bacterial growth(52, 69). 
TNF stimulated gene protein-6 (TSG6) is a major contributor to the immunomodulatory effects of 
MSCs and contributes to their benefit in a variety of conditions including myocardial infarction and 
wound healing(45, 70). This is also true of the MSC effect in lung injury. In an LPS-induced lung injury 
model MSCs significantly upregulate TSG6 production and the blockage of TSG6 by silencing RNA 
resulted in near complete reversal of their anti-inflammatory effects(71). Intriguingly, MSCs placed on 
nonadherent surfaces undergo compaction into spheroid aggregates. This triggers caspase-
dependent IL-1 signalling in MSCs subsequently augmenting the production of TSG6 in combination 
with other anti-inflammatory agents(72). The generation of these structures perhaps reflects what 
occurs in the pulmonary microvasculature and could partly explain their potent effects in lung injury 
models. 
MSCs also produce anti-inflammatory cytokines which partly contribute to the decreased 
inflammation in preclinical models. IL-1 receptor antagonist is produced by a subset of MSCs and 
was found in bleomycin-induced lung injury to prevent the upregulation of IL-1α and TNFα, two key 
inflammatory mediators in the lung(73). Prostaglandin E2 is a factor commonly associated with the 
MSC immunomodulatory effect and has been demonstrated to influence macrophages to increase 
production of anti-inflammatory IL-10 in a cecal ligation and puncture model of sepsis(74).  
It is important to note that whilst MSCs secrete an extensive range of anti-inflammatory cytokines, 
they are also capable of pro-inflammatory cytokine production in response to certain cues. IL-6 and 
IL-8 are secreted by MSCs, both of which have been associated with poorer outcomes in patients 
with ARDS(75, 76). IL-6 is often implicated in pro-inflammatory responses however it is apparent that 
this cytokine is promiscuous in its functions(77-79). Perhaps surprisingly, the therapeutic effects of 
murine MSCs from adipose tissue in an endotoxin-induced lung injury model were diminished with 
IL-6 interference(80). Whilst the role of MSC-derived IL-8 in lung injury is not clear, there is evidence 
that IL-8 is able to promote VEGF production by MSCs thereby supporting a pro-angiogenic effect(81). 
It is plausible that increased VEGF levels could provide a protective effect on the microvasculature in 
lung injury given the pro-survival influences that it exerts on endothelial cells(82, 83). It could also be 
argued that the potential for MSC-derived IL-8 to promote neutrophil recruitment in lung injury is 
abrogated by their concomitant production of TSG6, which is known to directly bind IL-8 
subsequently blocking this function(84).  
 
Nanotubule formation and microvesicle secretion 
MSCs are capable of secreting microvesicles, small membranous compartments containing bioactive 
molecules(85, 86). MSC-derived microvesicles alone were capable of attenuating E. coli induced lung 
injury in mice and recapitulating many of the therapeutic effects of the cells themselves, including 
decreases in pulmonary oedema and inflammation. mRNA coding KGF contained within these 
vesicles was partially responsible for this phenomenon(87).  
Interestingly, in vivo imaging depicts the formation of connexin-43 based gap junctions between 
MSCs and alveolar epithelial cells allowing the transport of mitochondria to the epithelia via 
microvesicles. The resultant increase in ATP levels concomitantly resulted in restoration of 
surfactant secretion by type II pneumocytes, reduced alveolar permeability and mortality in an LPS 
injury model(88). Another group also observed mitochondrial intercellular trafficking from MSCs to 
epithelial cells with the use of tunnelling nanotubules which was regulated by the Rho-GTPase 
Miro1(89). Although the mechanisms of effect of MSCs in the context of lung injury continue to be 
defined, it is already apparent that their actions are multifaceted, impacting on the numerous 
components of the pathophysiology of ARDS.  
MSCs in clinical trials of ARDS 
Following the success in preclinical studies MSCs have progressed rapidly to be tested in the clinic, 
with widespread study in diseases including steroid resistant acute graft versus host disease, Crohn’s 
disease and vascular disease(90-99). To date, studies investigating MSCs in ARDS has been primarily 
concerned with safety and feasibility of their delivery to patients(100). A randomized, placebo 
controlled pilot study carried out with the use of allogeneic adipose-derived MSCs (1x106 cells/kg of 
body weight, cells at passage of up to six) in patients with ARDS (defined by a PF ratio < 200mmHg) 
suggested that the treatment was not associated with any acute safety issues(101). There were no 
differences in duration of hospital stay, ventilator or ICU-free days, although the study was not 
powered for these clinical outcomes. There was a decrease in serum surfactant protein-D levels (a 
biomarker for type II alveolar epithelium injury/activation) although the significance of these data 
are unclear. 
A further recent multicentre, open-label, dose-escalation study sought to determine the safety and 
feasibility of administration of allogeneic bone-marrow derived MSCs in patients with moderate-to-
severe ARDS (defined as a PF ratio < 200mmHg receiving PEEP > 8cm H2O). The MSCs used here were 
at passage 2 and were administered in three doses; low dose (1x106 cells/kg), intermediate dose 
(5x106 cells/kg) and high dose (10x106 cells/kg). It was concluded that there were again no acute 
MSC-related adverse events in the study(102). The significance of the findings in these two studies are 
limited by the small patient numbers (12 and 9 respectively) and short follow-up but certainly justify 
progression to phase II clinical trials, which are currently underway (clinicaltrials.gov, NCT02097641). 
The long term effects of MSC treatment in patients of ARDS remain to be defined. 
It is important to note that in these studies only a single dose of MSCs was examined, with safety 
being the primary outcome. This is in contrast to trials in other diseases where multiple doses were 
given over an extended period of time (e.g. once weekly over four weeks in the case of Crohn’s 
disease(93) or twice weekly over four weeks for graft-versus-host-disease(98)) and were also found to 
be well tolerated and in some cases potentially efficacious in providing a therapeutic effect. Whilst it 
is possible that repeated doses of MSCs could be safe and more effective in ARDS, it is unwise to 
infer this based on findings from conditions so significantly different. Certainly, larger phase II 
studies elucidating the safety and efficacy of a single dose of MSCs are required before multiple 
dosing regimens should be investigated. 
Optimisation of the therapeutic effect of MSCs 
Preclinical research studying MSCs as a treatment modality is ongoing and there is a significant effort 
to maximise their effects. Numerous factors appear to have effects on the efficacy of MSCs in 
practice. For example, it is recognised that the route of administration can influence their benefit 
with intraperitoneal delivery more effective than intranasal in neonatal lung injury(60). This is further 
evidenced by the observation that intraperitoneal injection of MSCs is inferior to intratracheal or 
intravenous application in ventilator-induced lung injury(55). Another challenging task is to verify the 
optimal tissue source of MSCs. MSCs from different niches have distinctive attributes associated 
with them which may confer advantages depending on the context(103-105). For example, comparison 
of human bone marrow, adipose and umbilical cord MSCs shows that umbilical cord MSCs have 
higher proliferative rates and lower expression of senescence markers such as p53 and p21(104). This 
could suggest that umbilical cord MSCs would be more beneficial in regenerative applications. 
The ex vivo expansion of human MSCs and conditions they are exposed to prior to use has profound 
effects on their phenotype. Several studies have identified that maintenance of MSCs in hypoxic 
conditions alter MSC activity. Hypoxia, a characteristic feature of ARDS, is associated with 
heightened chemotaxis and cell viability coupled with upregulated secretion of paracrine factors(106). 
Hypoxic exposure of MSCs results in a higher proportion of self-renewing cells with a more 
homogenous population compared to cells maintained in normoxic conditions(107). Intriguingly, 
preconditioning MSCs in serum from ARDS patients before treating endotoxin-injured mice elicited a 
more potent IL-10 and IL-1ra response and consequentially improved outcomes(108). Preconditioning 
of MSCs in patient serum was also implemented by Zheng et al. in their adipose-tissue MSC clinical 
trial in ARDS patients(101). 
An understanding of how the local environment modifies MSC function has highlighted how MSCs 
might be manipulated to perhaps amplify their effects. Overexpression of soluble IL-1 receptor-like-1 
in MSCs, which competes with transmembrane IL-1 receptor-like-1, for IL-33 ligation, markedly 
increased the anti-inflammatory and reparative effects of these cells in endotoxin-induced lung 
injury compared to standard MSCs(109). IL-33 is expressed constitutively in the nuclei of epithelial and 
endothelial cells in many human tissues including the lung and is released upon damage. IL-33 is 
then able to elicit inflammatory responses(110, 111). MSCs transfected with a vector overexpressing 
angiopoietin-1 reduced inflammation and permeability to a greater extent in an LPS model of lung 
injury compared to control MSCs(112). MSC engraftment into the lung can be augmented through the 
blockage of the Wnt/β-catenin signalling pathway which normally acts to induce differentiation 
towards a fibroblast or myofibroblast phenotype(113).  
Another element regulating MSC function and phenotype is TLR stimulation. Waterman et al. 
described the induction of a pro-inflammatory MSC and immunosuppressive MSC phenotypes 
resulting from TLR4 and TLR3 stimulation respectively(114). TLR4-stimulated MSCs produced higher 
levels of pro-inflammatory IL-6 and IL-8, whereas TLR3 stimulation enhanced secretion of anti-
inflammatory IL-4 and IL-1ra. A conflicting study demonstrates that TLR3 stimulation resulted in the 
highest induction of IL-6 and IL-8 but the MSC sources between these studies differed(115). Moreover, 
the priming of bone marrow-derived MSCs with TLR3 and not TLR4 afforded the cells with increased 
resistance to NK cell killing as well as amplifying their immunosuppressive effects on these cells(116). 
Ongoing research in MSC therapy is crucial to uncover how the biological effects of MSCs can be 
potentiated to enable transition of MSCs to the bedside as the optimal treatment for patients with 
ARDS. 
MSC isolation and expansion quality control 
One of the major disadvantages limiting the progression of this cell therapy to the clinic is the poor 
characterisation of these cells in combination with the heterogeneity of their therapeutic effects. 
The European Medicines Agency and British Standards Institution both highlight the need for 
detailed profiling of MSCs, improved isolation and purification procedures and understanding of 
their mechanisms of action. The importance of MSC source and culture method is emphasized in 
comparative studies demonstrating substantial contrast in their immunomodulatory functions. For 
example, the use of foetal calf serum or platelet lysate for their expansion has significant effects on 
their abilities to inhibit T-cell growth(117). Other studies underline other key factors influencing MSC 
biology including the age of the donor or the levels of serum or glucose used in culture(118-120). 
As a result, there is significant work being carried out to create optimized methods of isolation and 
handling of MSCs(117, 121-124). Mimicking the bone marrow ECM which the MSCs inhabit in vivo results 
in improvements in their stemness and proliferative capacity(125). Furthermore, Carrancio and 
colleagues, when modifying a number of culture conditions for expansion, reported that platelet 
lysate supplementation and hypoxia resulted in the largest yields of MSCs expanded ex vivo(126).  
The inconsistency of the MSC effect in certain conditions could be attributed to any number of these 
variables related to their source, isolation and expansion. An emerging line of research, therefore, is 
the development of potency assays for MSCs which could be used before administration to patients. 
Expression of TSG6 appears to correlate with their anti-inflammatory potency in a model of chemical 
injury to the cornea but conversely its expression was negatively associated with osteogenic 
differentiation capacity(127). Use of a combination of simple in vitro assays enabled the efficacy of 
bone marrow-derived MSCs in treatment of murine wounds to be defined(128). These assays 
determined MSC growth, proliferation and viability using cell counts, bromodeoxyuridine 
incorporation and measurement of cellular ATP levels respectively. Higher scoring in these assays 
was associated with more extensive engraftment into the wound site. 
It is therefore critical that isolation, expansion and screening procedures for MSCs in the treatment 
of lung injury be optimized and standardized.  
Summary 
There remains urgent need for an effective therapy for ARDS. MSCs are a highly versatile cell 
population with potential implications as a treatment for ARDS based on their immunomodulatory 
capacity, reparative properties, ease of isolation and propagation and the feasibility as an allogeneic 
therapy. A wealth of evidence supports the case for MSC based therapy in patients with ARDS and 
has paved the way for ongoing clinical trials. However much remains to be defined about the role of 
MSCs in ARDS. The importance of further investigation of MSCs cannot be overstated and is 
necessary to determine the most appropriate application of MSCs and optimising their therapeutic 
effects in ARDS.   
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